Comparative gene expression profiling of MHH-CALL4 cells subject to pharmacological JAK2 inhibitor treatment (ruxolitinib or CHZ868) or shRNA-mediated JAK2 depletion in vitro. Homo sapiens

Gene expression profiling was performed to characterise transcriptional programs associated with response to type I JAK2 inhibitor ruxolitinib, type II JAK2 inhibitor CHZ868 or shRNA-mediated JAK2 knockdown in MHH-CALL4 cells. Overall design: CRLF2-rearranged/JAK2I682F-expressing MHH-CALL4 cells were treated with vehicle (DMSO), CHZ868 (300 nM) or ruxolitinib (1000 nM) for 24 hours in duplicate and total RNA was freshly extracted for 3'-RNA-Seq. MHH-CALL4 cells were transduced with constitutive (pLMS-GFP) retroviral vectors harbouring shRNAs targeting JAK2 (shJAK2.209 or shJAK2.2826) or scrambled (shSCR) in duplicate and GFP+ cells were harvested at day 5 post-transduction for 3'-RNA-Seq.